Melanocortins and Interleukins Contributing to Advanced Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in Patients With BMI ≥ 40

被引：0
|
作者：
Baranova, Ancha
Jarrar, Mohammed
Moazzez, Amir H.
Elariny, Hazem
Abawi, Massih
Wang, Lei
Afendy, Arian
Stepanova, Maria
Estep, J. M.
Younossi, Zobair M.
机构：
来源：
OBESITY | 2011年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation
    Burke, A
    Lucey, MR
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (05) : 686 - 693
  • [42] Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: A systematic review and meta-analysis
    Mounika, Nadella
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 323 - 323
  • [43] Aminotransferse Levels are not Predictive of Histologic Activity or Stage in Morbidly Obese Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
    Birerdinc, Aybike
    Lei, Wang
    Ozcan, Kenan
    Nguyenngo, Cartherine
    Estep, Michael
    Afendy, Arian
    Baranova, Ancha
    Younossi, Zobair
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S116 - S117
  • [44] SERUM DES-ACYLGHRELIN CONCENTRATION IS ASSOCIATED WITH HISTOLOGIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Estep, M.
    Vernon, G.
    Wang, L.
    Stepanova, M.
    Younoszai, A.
    Elariny, H.
    Goodman, Z.
    Chandhoke, V.
    Baranova, A.
    Younossi, Z.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S350 - S351
  • [45] Expression of Genes Associated With Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in the Gastric Tissue of Patients Undergoing Bariatric Surgery
    Birerdinc, Aybike
    Mehta, Rohini
    Moazzez, Amir H.
    Elariny, Hazem
    Stepanova, Maria
    Baranova, Ancha
    Younossi, Zobair M.
    OBESITY, 2011, 19 : S88 - S88
  • [46] CHARACTERIZING AND PREDICTING NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS IN NON-OBESE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN ASIA - THE GOASIA INITIATIVE.
    Lee, Wei Jie Jonathan
    Tan, Xiang Xuan Eunice
    Chan, Wah Keong
    Treeprasertsuk, Sombat
    Goh, George Boon Bee
    Fan, Jian-Gao
    Song, Myeong Jun
    Charatcharoenwitthaya, Phunchai
    Duseja, Ajay K.
    Imajo, Kento
    Nakajima, Atsushi
    Seki, Yosuke
    Kasama, Kazunori
    Kakizaki, Satoru
    Lesmana, Laurentius A.
    Ho, Khek Yu
    Goh, Khean Lee
    Wong, Vincent Wai-Sun
    Dan, Yock Young
    HEPATOLOGY, 2019, 70 : 25A - 26A
  • [47] Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease
    Kim, Jeong Woo
    Lee, Chang Hee
    Kim, Baek-Hui
    Lee, Young-Sun
    Hwang, Soon-Young
    Park, Bit Na
    Park, Yang Shin
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2022, 12 (03) : 1815 - 1829
  • [48] Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
    Daher, Saleh
    Cohen, Namma Lev
    Massarwa, Muhammad
    Mahamid, Mahmud
    Nasser, Mira
    Hazou, Wadi
    Oren, Rani
    Safadi, Rifaat
    Khoury, Tawfik
    PLOS ONE, 2018, 13 (11):
  • [49] Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
    Bifari, Francesco
    Manfrini, Roberto
    Cas, Michele Dei
    Berra, Cesare
    Siano, Matteo
    Zuin, Massimo
    Paroni, Rita
    Folli, Franco
    PHARMACOLOGICAL RESEARCH, 2018, 137 : 219 - 229
  • [50] Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
    Laddha, Ankit P.
    Dzielak, Lindsey
    Lewis, Cedric
    Xue, Raymond
    Manautou, Jose E.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (03):
12345